COMPASS Pathways公司宣布，针对其创新疗法Comp360在治疗耐药性抑郁症领域的应用，已与美国食品药品监督管理局（FDA）展开滚动申报程序的合作。这一进展标志着该公司在精神健康治疗领域的研发迈出关键一步。
COMPASS Pathways公司宣布，针对其创新疗法Comp360在治疗耐药性抑郁症领域的应用，已与美国食品药品监督管理局（FDA）展开滚动申报程序的合作。这一进展标志着该公司在精神健康治疗领域的研发迈出关键一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.